DAVENPORT & Co LLC Sells 37,653 Shares of Sanofi $SNY

DAVENPORT & Co LLC lowered its position in Sanofi (NASDAQ:SNY) by 1.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,042,341 shares of the company’s stock after selling 37,653 shares during the quarter. DAVENPORT & Co LLC owned 0.08% of Sanofi worth $99,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Advisory Services Network LLC grew its holdings in Sanofi by 1.4% during the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after acquiring an additional 210 shares during the last quarter. Waterfront Wealth Inc. raised its stake in shares of Sanofi by 0.4% during the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock valued at $2,463,000 after acquiring an additional 214 shares during the last quarter. HighPoint Advisor Group LLC lifted its holdings in shares of Sanofi by 2.3% during the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock worth $468,000 after purchasing an additional 226 shares during the period. HM Payson & Co. lifted its holdings in shares of Sanofi by 3.4% during the third quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after purchasing an additional 235 shares during the period. Finally, Leonard Rickey Investment Advisors P.L.L.C. grew its stake in shares of Sanofi by 4.7% in the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock worth $252,000 after purchasing an additional 238 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Weiss Ratings lowered Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Guggenheim downgraded Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Finally, HSBC reaffirmed a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $61.50.

Sanofi Price Performance

SNY stock opened at $45.14 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The firm has a market cap of $110.10 billion, a price-to-earnings ratio of 12.54, a PEG ratio of 1.16 and a beta of 0.45. The company’s fifty day simple moving average is $46.36 and its 200 day simple moving average is $48.01. Sanofi has a 12-month low of $43.32 and a 12-month high of $56.93.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.